A Phase 2 interventional study of WX-081 and Bedaquiline in Pulmonary Tuberculosis, sponsored by Shanghai Jiatan Pharmatech Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-09-11.
Sponsored by Shanghai Jiatan Pharmatech Co., Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Tuberculosis, Pulmonary with a site in China — 12 open to participants now, 14 under way, 6 of them phase 3. Tuberculosis, Pulmonary · China.
Among the 28 studies in Tuberculosis, Pulmonary with a site in China, this one is the 19th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2020, is one of 4 in phase 2, and was the 12th registered.
319 studies on the registry are indexed under Tuberculosis, Pulmonary; 71 are open to participants now.
Browse Tuberculosis, Pulmonary studies →12 of the 28 studies in Tuberculosis, Pulmonary with a site in China are open now. Recruiting first, the newest first:
Huashan Hospital · Sites in China
Ages 3 mo–18 yrs
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18+
Shenzhen Third People's Hospital · Sites in China
Ages 18–65
ChromX Health · Sites in China
Ages 18–100 · Healthy volunteers
Beijing Chest Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 46 Tuberculosis, Pulmonary studies recruiting now, 22 (48%) set no upper age limit and 20 (43%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 7 · Phase 4 6
First in 2008; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 99 is below the median of 146 across 227 interventional studies indexed under Tuberculosis, Pulmonary.
Median enrollment 280 across the 21 interventional studies, 800 across the 7 observational. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 28 have an industry lead sponsor. The 10 most frequent:
Shanghai Jiatan Pharmatech Co., Ltd is the lead sponsor of 11 studies on the registry; 7 are open to participants now.
Shanghai Jiatan Pharmatech Co., Ltd has 3 studies filed under Tuberculosis, Pulmonary — fewer than ten, so there is no comparison to draw.
4 of the studies in Tuberculosis, Pulmonary with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06649721Phase 3Huashan HospitalInnovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis:BDLL Chinese Cohort | 2027-02-28 |
| NCT07395596First Affiliated Hospital of Zhejiang UniversityRemimazolam for Bronchoscopy in High-Risk Patients | 2026-12 |
| NCT06528418ChromX HealthIdentification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath | 2026-12-30 |
| NCT07893444Huashan HospitalBRIGHT-Child TB: Short-Course Treatment for Non-Severe Pulmonary Tuberculosis in Children | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 28 studies in Tuberculosis, Pulmonary with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, randomized, parallel, open-label, positive-controlled Phase 2 clinical trial, which aims to evaluate the early bactericidal activity, safety and tolerability of WX-081 in patients with drug-naive\&susceptible and drug-resistant tuberculosis. Also the efficacy of WX-081 will be explored in participants with drug-resistant tuberculosis.
This is a Phase 2, multi-center, randomized, parallel, open-label, positive-controlled clinical trial. The objective of this trial is to evaluate the early bactericidal activity, safety and tolerability of WX-081 patients with drug-naive\&susceptible and drug-resistant tuberculosis. and the efficacy in participants with drug-resistant tuberculosis.
This trial will be divided into core research stage (stage 1) and extended research stage (stage 2). During stage 1, a panel of 59 participants with drug-naive\&susceptible tuberculosis will be randomized to receive either WX-081(including 3 groups:150mg qd, 300mg qd, 450mg qd. n=12 per group) or standard treatment (n=8) for 2 weeks, and then followed by a follow-up period of 2 weeks. A panel of 40 participants with drug-resistant tuberculosis will be randomized to receive either WX-081 (400mg qd, n=20) or bedaquiline (400mg qd, n=20) for 2 weeks. During stage 2, the 40 participants with drug-resistant tuberculosis will receive WX-081(150mg qd) + MBT treatment (ie. multi-drug background treatment) and bedaquiline (200mg tiw) +MBT treatment for 6 weeks respectively, and then followed by a follow-up period of 4 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with newly-treated drug sensitivity tuberculosis receive WX-081 150mg orally once daily for 2 weeks.
Drug: WX-081
Participants with newly-treated drug sensitivity tuberculosis receive WX-081 300mg orally once daily for 2 weeks.
Drug: WX-081
Participants with newly-treated drug sensitivity tuberculosis receive WX-081 450mg orally once daily for 2 weeks.
Drug: WX-081
Participants with newly-treated drug sensitivity tuberculosis receive standard treatment for two weeks.
Drug: Standard treatment
Participants with drug-resistant tuberculosis receive WX-081 400mg orally once daily for 2 weeks, and then MBT+ WX-081 150mg orally once daily for 6 weeks.
Drug: WX-081 · Drug: Multi-drug background treatment (MBT)
Participants with drug-resistant tuberculosis receive Bedaquiline 400mg orally once daily for 2 weeks, and then MBT+ Bedaquiline 200mg orally 3 times per week for 6 weeks.
Drug: Bedaquiline · Drug: Multi-drug background treatment (MBT)
WX-081 is not licensed yet. WX-081 will be used in arms A, B, C, WX-081+MBT.
This licensed drug will be used in arm F as positive comparator.
Standard treatment will be used in arm D as positive comparator, according to the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.
MBT will be used in arm E, F as background treatment. The drugs used in MBT are all licensed drugs, and the treatment complies with the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.
Time to positive (TTP)
TTP is measured as time to sputum culture positivity in Liquid Culture Media.
Time frame: Day 0-14.
Early bactericidal activity (EBA) of WX-081
EBA is measured as the mean rate of colony forming unit (log10CFU) of mycobacterium tuberculosis per ml sputum on solid medium in different time periods.
Time frame: Day 0-14.
change of electrocardiogram QT interval
QT interval is calculated as QTcF in milliseconds (ms)
Time frame: Measured through 8 Weeks.
The percentage of participants with sputum culture-negative conversion.
Percentage of participants with an occurrence of sputum culture-negative through 8 weeks.
Time frame: Measured through 8 Weeks.
Rate of change of colony forming units (CFU)
Rate of change of colony forming units (CFU) of mycobacterium tuberculosis on sputum culture through 8 weeks.
Time frame: Measured through 8 Weeks.
The percentage of participants with sputum smear-negative conversion.
Percentage of participants with an occurrence of sputum smear-negative through 8 weeks.
Time frame: Measured through 8 Weeks.
heart rate
heart rate in times per minute.
Time frame: Measured through 8 Weeks.
blood pressure
blood pressure in mmHg
Time frame: Measured through 8 Weeks.
Maximum plasma concentration (Cmax)
Blood samples will be taken at different time points before and after administration on Day1 and Day14 of treatment.
Time frame: At day1 and 14.
Time to reach maximum plasma concentration (Tmax)
Blood samples will be taken at different time points before and after administration on Day1 and Day14 of treatment.
Time frame: At day1 and 14.
Area under the plasma concentration versus time curve (AUC(0-t))
Blood samples will be taken at different time points before and after administration on Day1 and Day14 of treatment.
Time frame: At day1 and 14.
Terminal plasma half-life (t1/2)
Blood samples will be taken at different time points before and after administration on Day1 and Day14 of treatment.
Time frame: At day1 and 14.
Plan to share: No
Ran from Oct 2020 to primary completion in Apr 2022, 17 months.
Of 43 phase 2 interventional studies under Tuberculosis, Pulmonary, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 37. This study's 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sudapyridine
Shanghai Jiatan Pharmatech Co., Ltd